Compare Heron Therapeutics Inc (HRTX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs PepsiCo, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while PepsiCo, Inc. trades at $135.3 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 2021.5× Heron Therapeutics Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PEP | |
|---|---|---|
Market Cap | $91.46M | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $1.96 | $170.44 |
52-Week Low | $0.39 | $135.40 |
Enterprise Value | $189.36M | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
PepsiCo (PEP) trades at $137.12, down 1.66% on the day, with technical indicators showing bearish momentum. The stock demonstrates strong fundamentals with consistent earnings beats, a 10.78% net income margin, and robust cash flow generation. Recent news highlights price adjustments on snack products and sponsorship withdrawals, while analysts maintain a predominantly hold rating with a $158.50 consensus price target representing 15.6% upside potential.
The outlook remains cautiously optimistic given PEP's stable dividend yield and operational resilience, though near-term headwinds include consumer price sensitivity and competitive pressures. The upcoming Q3 2026 earnings report on April 16 will be critical for validating the North American turnaround narrative and margin expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
